Its a key part of protecting patient health
In Type 2 diabetes, where beta cells often deteriorate, GLP-1 helps slow disease progression and maintain endogenous insulin production
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
If you dont have a primary care physician, consider joining an MDVIP-affiliated practice
These contrasting findings might be explained by substantial differences in study design, sample, and reward phase